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Congenital anomalies such as meningomyelocele and diseases/damage of the central, peripheral, or autonomic nervous systems
may produce neurogenic bladder dysfunction, which untreated can result in progressive renal damage, adverse physical
eﬀects including decubiti and urinary tract infections, and psychological and social sequelae related to urinary incontinence.
A comprehensive bladder-retraining program that incorporates appropriate education, training, medication, and surgical
interventions can mitigate the adverse consequences of neurogenic bladder dysfunction and improve both quantity and quality of
life. The goals of bladder retraining for neurogenic bladder dysfunction are prevention of urinary incontinence, urinary tract
infections, detrusor overdistension, and progressive upper urinary tract damage due to chronic, excessive detrusor pressures.
Understanding the physiology and pathophysiology of micturition is essential to select appropriate pharmacologic and surgical
interventionstoachievethesegoals.Futureperspectives onpotentialpharmacological, surgical,andregenerativemedicineoptions
for treating neurogenic bladder dysfunction are also presented.
1.Background
Normal micturition involves proper function of both the
bladder and urethra. A detrusor of normal compliance
and a physiologically competent urethral sphincter are both
necessary to maintain urinary continence. Any increase in
abdominal pressure, which inherently produces an increase
in bladder pressure, is normally counteracted by an even
greater increase in urethral pressure.
Normal micturition involves passive, low pressure ﬁlling
of the bladder during the urine storage phase while voiding
requires coordination of detrusor contraction with internal
and external urinary sphincter relaxation. This micturition
process is controlled by the central nervous system, which
coordinates the sympathetic and parasympathetic nervous
system activation with the somatic nervous system to ensure
normal micturition with urinary continence [1].
Voiding dysfunction can result from any mechanical or
physiologic defects in the micturition system that result
in the inability of the urinary sphincter to appropriately
increase (or decrease) its pressure in response to increased
bladder pressure. Damage or diseases of the central, periph-
eral, and autonomic nervous systems may result in neuro-
genic bladder dysfunction.
Neurogenic bladder dysfunction may complicate a vari-
etyofneurologicconditions.IntheUnitedStates,neurogenic
bladder aﬀects 40–90% of persons with multiple sclerosis,
37–72% of those with Parkinsonism, and 15% of those
with stroke [2]. Detrusor hyperreﬂexia is seen in 50–
90% of persons with multiple sclerosis, while another 20–
30% have detrusor areﬂexia. There are more than 200,000
persons with spinal cord injuries, and 70–84% of these
individuals have at least some degree of bladder dysfunc-
tion [3]. Bladder dysfunction is also common in spina
biﬁda, which aﬀects approximately 1 per 1000 live births.
V e s i c o u r e t e r a lr e ﬂ u xm a yo c c u ri nu pt o4 0 %o fc h i l d r e n
with spina biﬁda by age 5, and up to 61% of young
adults with spina biﬁda experience urinary incontinence
[4]. Less common causes of neurogenic bladder include
diabetes mellitus with autonomic neuropathy, pelvic surgery
sequelae, and cauda equina syndrome due to lumbar spine
pathology.2 Advances in Urology
Manack et al. [3] examined insurance and pharmacy
claimsofnearly60,000patientswithneurogenicbladderover
a 4-year period and found a 29–36% rate of lower urinary
tract infections, 9–14% rate of urinary retention, and a 6–
11% rate of urinary tract obstructions. Upper urinary tract
infections were noted in 1.4–2.2% of the neurogenic bladder
cohort, and serious systemic illnesses were also diagnosed in
this group including septicemia in 2.6–4.7% and acute renal
failure in 0.8–2.2%. Neurogenic bladder patients averaged 16
oﬃce and 0.5 emergency room visits per year, approximately
a third of them leading to hospitalization.
Neurogenicbladderwithdetrusoroveractivitymaycause
incontinence, which not only leads to embarrassment,
depression and social isolation but also may lead to skin
decubiti, urethral erosions, and upper urinary tract damage
[5].
2. Anatomy and Physiology of the Bladder
The basic neuroanatomy and neurophysiology of the upper
and lower urinary tracts should be understood before
considering bladder management issues. Normal voluntary
micturition includes bladder ﬁlling, storage, and emptying
[1]. The kidneys receive nearly 25% of the cardiac output,
ﬁltering 180L per day though only approximately 1L/day
is excreted as urine. This ﬁltrate is transported through the
ureters to the bladder. The ureters, which are approximately
25–30cm in length, pass obliquely through bladder wall at
the ureterovesicular junction to form a one-way valve that
serves to prevent retrograde reﬂux of urine to the kidneys
during bladder ﬁlling and emptying stages. This one-way
valve mechanism remains competent only as long as the
oblique course of the ureters is maintained thru the bladder
wall. The bladder stores urine in a low pressure system with
a normal capacity of 400–500cc. Anatomically, the bladder
is divided into the detrusor (aka as “body” or “dome” of
the bladder), which consists of smooth muscle, and the
base, which includes the trigone and bladder neck that are
intimately connected to the pelvic ﬂoor. The bladder outlet
has two urethral sphincters, the internal (smooth muscle)
sphincter in the bladder neck and proximal urethra and
the external (striated muscle) sphincter of the membranous
urethra. Females have a less complex urinary sphincter
mechanism that surrounds a shorter urethra.
Regulation of micturition involves cortical, subcorti-
cal, brainstem, spinal cord, and bladder mechanisms (see
Figure 1). Cortical control areas in the frontal and cingulate
gyri as well as subcortical areas provide inhibitory inﬂuence
on micturition at the level of the pons and excitatory
inﬂuence on the external urinary sphincter. This allows
voluntary control of micturition so that normally bladder
evacuation can be delayed until an appropriate time and
place to void are chosen.
The pontine micturition center (PMC, also known as
Barrington’s nucleus or M-region) is essential for the coor-
dination of micturition. This is accomplished by the PMC
modulating the opposing eﬀects of the parasympathetic and
sympathetic nervous systems on the lower urinary tract. In
the bladder emptying stage, the PMC sends excitatory inﬂu-
encetothesacralspinalcordthatproducesdetrusorcontrac-
tionwhilesimultaneouslysendinginhibitoryinﬂuencetothe
thoracolumbarcordthatproducesinternalurinarysphincter
relaxation. The overall eﬀect is to allow evacuation of the
bladder contents. Conversely, during bladder storage phase,
PMC inhibition causes suppression of sacral spinal cord that
produces detrusor relaxation while simultaneously sending
excitatoryinﬂuencetothethoracolumbarcordthatproduces
internal urethral sphincter contraction. The overall eﬀect is
to allow ﬁlling/storage of urine in the bladder. More details
of these mechanisms will be discussed further below.
Ascending sensory information on the state of bladder
ﬁlling is believed to reach the periaqueductal gray (PAG)
matter where it is then relayed via the hypothalamus
and thalamus to the anterior cingulate cortex, insula, and
prefrontalcortex.ThesebrainregionsinhibitthePAG,which
itself has excitatory input to the PMC. The hypothalamus
has excitatory inﬂuence on the PAG. When the conscious
decision to void occurs, the prefrontal cortex inhibition of
the PAG is interrupted while simultaneously the hypothala-
musstimulatesthePAG.Theoverallresultisexcitationofthe
PMC which produces voiding.
Spinal neurons involved in the regulation of micturition
are located in the dorsal commissure, superﬁcial dorsal horn,
and parasympathetic nucleus. Interneurons send rostral
projections but also serve to regulate spinal segmental
reﬂexes. Glutamate serves as the excitatory transmitter at the
spinal level while glycine and γ-aminobutyric acid (GABA)
are the inhibitory neurotransmitters.
Three mixed sensory and motor nerves (hypogastric,
pelvic, and pudendal nerves) innervate the lower urinary
tract. The hypogastric nerve carries sympathetic autonomic
nervous system innervation, the pelvic nerve carries the
parasympathetic autonomic nervous system innervation,
and the pudendal nerve carries the somatic nervous system
innervation to the lower urinary tract.
As shown in the Figure 1, sympathetic nervous system
innervation to the lower urinary tract arises from the T11-
L2 cord level to synapse in the inferior mesenteric and
hypogastric plexuses before continuing via the hypogastric
nerves to α-adrenergic receptors in the bladder neck and
proximal urethra as well as β-adrenergic receptors in the
bladder fundus. Sympathetic nerve ﬁbers also innervate
parasympathetic ganglia in the detrusor wall and have an
inhibitory eﬀect on those ganglia. Activation of the tho-
racolumbar sympathetic outﬂow produces norepinephrine
release in the lower urinary tract that results in detrusor
relaxationandbladderneck(internalsphincter)contraction.
Parasympatheticnervoussysteminnervationtothelower
urinary tract arises from the detrusor nucleus at the S2–
S4 cord level (see Figure 1) which passes through the pelvic
nerves to cholinergic parasympathetic neurons in ganglia in
the detrusor. Acetylcholine released by activation of these
neurons produces detrusor contraction through M2 and
M3 muscarinic receptor activation, though M1 receptors are
alsopresentinprejunctionalneuronalterminals.Parasympa-
thetic innervation in the proximal urethra causes nitric oxide
to be released there which produces urethral smooth muscleAdvances in Urology 3
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Figure 1:Anatomyandphysiologyofmicturitionwithpotentialinjurysitestourologicsystem(m:muscarinicreceptor, α:alpha-adrenergic
receptor, β: beta-adrenergic receptor).
relaxation. Activation of the sacral parasympathetic outﬂow
produces acetylcholine and nitric oxide in the lower urinary
tractthatresultsindetrusorcontractionandrelaxationofthe
proximal urethra.
Somatic nervous system innervation to the external
urethralsphincterarisesfromthepudendal(Onuf’s)nucleus
at the S2–S4 cord level which then passes through the
pudendal nerve to the sphincter striated muscle. Supraspinal
centers, which normally are under voluntary control, pro-
duceexcitatoryinﬂuenceonthepudendalnucleusduringthe
bladder ﬁlling stage to produce external urethral sphincter
and pelvic ﬂoor contraction to help maintain continence,
while during bladder voiding stage this descending inﬂuence
is inhibited to produce urethral and pelvic ﬂoor relaxation
that facilitates bladder emptying.
Aﬀerent information on the state of bladder ﬁlling
is transmitted from sensory ﬁbers in dense suburothelial
and muscular plexuses. Some sensory ﬁbers may extend
through the urothelium into the bladder cavity to transduce
both physical and chemical stimuli. The vast majority of
these sensory aﬀerents are small myelinated Aδ ﬁbers and
unmyelinatedCﬁbers.TheAδ ﬁbersrespondtobladderwall
distention and trigger micturition, while C ﬁbers respond to
painful stimuli. The majority of the bladder aﬀerent ﬁbers
run in the pelvic nerves to the sacral dorsal root ganglia, and
after transduction of these signals in the dorsal horn of the
spinal cord, this sensory information is transmitted rostrally
to the PAG region, as previously described.
During the bladder ﬁlling stage, supraspinal centers
produce inhibition of the pontine micturition center, which
results in enhancement of thoracolumbar sympathetic out-
ﬂow with simultaneous suppression of sacral parasympa-
thetic outﬂow to the lower urinary tract. These supraspinal
centers also produce excitatory outﬂow through the puden-
dal nerve to produce external urethral sphincter contraction.
The overall eﬀect in normal bladder physiology is detrusor
smooth muscle relaxation, bladder neck smooth muscle
contraction, and external urinary sphincter skeletal muscle
contraction that allow low pressure storage of urine in the
bladder without leakage.4 Advances in Urology
During the bladder emptying phase, the supraspinal
centers’ inhibitory outﬂow to the pontine micturition center
is suppressed, resulting in reduction of thoracic sympa-
thetic outﬂow with simultaneous enhancement of sacral
parasympathetic outﬂow to the lower urinary tract. The
supraspinalcenters’excitatoryoutﬂowthroughthepudendal
nerve is suppressed producing external urethral sphincter
relaxation. The overall eﬀect in normal bladder physiology is
detrusor smooth muscle contraction, bladder neck smooth
muscle relaxation, and external urinary sphincter skeletal
musclerelaxationthatallowevacuationofurinestoredinthe
bladder.
3. Pathophysiology of Neurogenic Bladder
Many classiﬁcations have been used to group neurogenic
bladderdysfunction.Eachhastheirmeritsandclinicalutility.
These classiﬁcations may be based on urodynamic ﬁndings
(e.g., Lapides [6], Krane, and Siroky [7]), neurourologic
criteria (Hald and Bradley [8], Bors and Comarr [9]), or
on bladder and urethral function (International Continence
Society [10], Wein [11]).
A popular classiﬁcation of neurogenic bladder dysfunc-
tion based on the location of the neurologic lesion can help
guidepharmacologicandsurgicaltherapies,withthevoiding
abnormalities seen clinically following from disruptions of
the normal urinary physiology described above and shown
in Figure 1. In this classiﬁcation, neurogenic bladder arises
from
(1) lesions above the pontine micturition center (e.g.,
stroke or brain tumor) producing an uninhibited
bladder,
(2) lesions between the pontine micturition center and
sacral spinal cord (e.g., traumatic spinal cord injury
or multiple sclerosis involving cervicothoracic spinal
cord) producing an upper motor neuron bladder,
(3) sacral cord lesions that damage the detrusor nucleus
but spare the pudendal nucleus producing a mixed
type A bladder,
(4) sacralcordlesionsthatsparethedetrusornucleusbut
damagethepudendalnucleusproducingamixedtype
B bladder,
(5) lowermotorneuronbladder fromsacralcordorsacral
nerve root injuries.
In uninhibited neurogenic bladder dysfunction, there is
usually reduced awareness of bladder fullness and a low
capacity bladder due to reduction of inhibition of the pon-
tine micturition center (PMC) by cortical and subcortical
structure damage. Urinary incontinence may occur with
brainlesionsoccurringabovethepontinemicturitioncenter,
especially with bilateral lesions. Since the PMC is intact,
the normal opposition of detrusor and internal/external
sphincter tonus is maintained so there are no high bladder
pressures developed that can lead to upper urinary tract
damage.
Upper motor neuron neurogenic bladder dysfunction
is characterized by detrusor-sphincter dyssynergia (DSD),
wherein simultaneous detrusor and urinary sphincter con-
tractions produce high pressures in the bladder (up to
80–90cm H2O) leading to vesicoureteral reﬂux that can
produce renal damage. The spinal cord damage renders the
bladder and sphincters spastic, especially if lesions are above
the T10 level (above the sympathetic autonomic nervous
system innervation of the bladder). The bladder capacity is
usually reduced due to the high detrusor tonus (neurogenic
d e t r u s o ro v e r a c t i v i t y ,o rd e t r u s o rh y p e r r e ﬂ e x i a ) .A n i m a l
studies suggest that activation of prejunctional M1 receptors
facilitates acetylcholine release, so excessive release of this
neurotransmitter due to upper motor neuron lesions may
be a mechanism by which neurogenic detrusor overactivity
occurs. As the bladder hypertonicity produces hypertrophy
of the detrusor muscle, the normal oblique course of the
ureter through the detrusor wall at the ureterovesicular
junction is compromised to allow vesicoureteral reﬂux. If
detrusorpressureexceedsinternal/externalurinarysphincter
pressure in the proximal urethra, then incontinence may
occur.
In the mixed type A neurogenic bladder (the more
common of the mixed type bladders), detrusor nucleus
damage renders the detrusor ﬂaccid (also referred to as
detrusorareﬂexia),whiletheintactpudendalnucleusisspas-
tic producing a hypertonic external urinary sphincter. The
bladder is large and has low pressure, so the spastic external
sphincter produces urinary retention. The detrusor pressure
is low so upper urinary tract damage from vesicoureteral
reﬂux does not occur, and incontinence is uncommon.
The mixed type B neurogenic bladder is characterized
by a ﬂaccid external urinary sphincter due to the pudendal
nucleus lesion while the bladder is spastic due to the
disinhibited detrusor nucleus. Thus, the bladder capacity is
low but vesicular pressures are usually not elevated since
there is little outﬂow resistance. This leads to problems with
incontinence, however.
In lower motor neuron neurogenic bladder, the sacral
micturition centers or related peripheral nerves are damaged
though the thoracic sympathetic nervous system outﬂow
to the lower urinary tract is intact. The bladder capacity
is large since detrusor tone is low (detrusor areﬂexia) and
internal urinary sphincter innervation is intact. Despite the
low detrusor pressure, overﬂow urinary incontinence and
urinary tract infections are not uncommon.
Another type of bladder dysfunction was ﬁrst described
in nursing home residents, termed detrusor hyperactivity
withimpairedbladdercontractility(DHIC),inwhichthereis
frequent but weak involuntary detrusor contractions causing
incontinence despite incomplete bladder emptying [12]
(Resnick). DHIC is associated with bladder trabeculation,
slow bladder contraction velocity, and elevated urinary
residual volume after voiding attempts.
4.NeurourologicalEvaluation
This evaluation is essential to assess lower urinary tract
function.Advances in Urology 5
A full patient history should be obtained including prior
genitourinary conditions/surgeries, voiding history, voiding
complaints (dysuria, recurrent infections, hesitancy, noc-
turia, incontinence, urgency, and/or frequency), and med-
ications. Sedative/hypnotic, antidepressant, antipsychotic,
antihistamine, anticholinergic, antispasmodic, opiate, alpha
adrenergic agonists/antagonists, and calcium channel block-
ing medications may aﬀect voiding function. Optimally, a
patient urinary diary with voiding pattern, ﬂuid intake, and
voiding issues can help with the patient evaluation and
formulation of treatment recommendations.
A physical examination focusing on pelvic anatomy and
the neurologic system is essential. Neurological examination
should include mental status, reﬂexes, strength, and sensa-
tion (including sacral dermatomes) to determine if there
are neurologic conditions present that may contribute to
the voiding dysfunction. Mechanical issues such as prostate
enlargement or bladder prolapse can be found on urologic
exam that may impact voiding function. Issues with cog-
nition, hand strength and coordination, joint contractures,
mobility, sexuality, social/medical support, and other factors
may impact the type of bladder rehabilitation that is feasible
for a given patient. For spinal cord injured patients, the
motor level of spinal lesion, whether the injury is complete
or incomplete, extremity tone, rectal sensation/tone, pres-
ence/absence of voluntary rectal tone, and bulbocavernosus
reﬂex should be determined.
Laboratory evaluation of neurogenic bladder patients
should include urinalysis, urine culture and sensitivity,
serum BUN/creatinine, and creatinine clearance [13]. Post-
void residual (PVR) urine volume involves transurethral
catheterization to measure residual urine volume in the
bladder immediately after voiding to determine the ability of
the bladder to empty completely. PVR determination should
always be performed after discontinuing Foley catheteriza-
tion or before instituting intermittent catheterization as part
of a bladder retraining program. The PVRs are necessary
to prevent overdistension of the bladder and determine the
frequency of catheterization that is needed to keep residual
urinary volumes under approximately 400cc. Abnormal
residual volumes have been deﬁned by volumes greater than
100ccorgreaterthan20%ofthevoidedvolume,andresidual
urine volumes under 100cc are associated with a reduced
risk of development of bacterial cystitis [14]. Ultrasound is
a noninvasive means of determining urine post-void residual
volumes, especially if precise measurement is not required
[15].
Renal clearance tests including twenty-four-hour urine
creatinine clearance and several isotope studies can be
used to evaluate and sequentially follow renal function in
neurogenicbladderpatients.Acommonlyusedtestmeasures
the glomerular ﬁltration rate via a short renal clearance test
using 125 I-iothalamate [16].
Urodynamic evaluation should be completed to assess
urinary function, including urinary ﬂowmetry, bladder cys-
tometrogram/electromyogram (CMG/EMG), Valsalva leak
point pressure (LPP) measurement, and urethral pressure
proﬁle (UPP). Urodynamic studies are the most deﬁnitive
and objective means to determine abnormalities in the
bladder and urethra in the ﬁlling/storage phase as well as
voiding phase in neurogenic bladder dysfunction.
Urinary ﬂow rate evaluation is a noninvasive way to
quantify urinary ﬂow, deﬁned as the volume of urine voided
per unit of time. Urine ﬂow is dependent on the force
of detrusor contraction as well as the urethral resistance.
Normal urine ﬂow curves are bell-shaped with rapid rise
to peak ﬂow, a short duration of peak ﬂow, and then
rapid falloﬀ of urine ﬂow. Urine ﬂow rate patterns are not
diagnostic,buthighﬂowratesareoftenseenwithneurogenic
detrusor overactivity, and poor ﬂow rates may reﬂect weak
detrusor pressure and/or urinary outlet obstruction.
The bladder cystometrogram/electromyogram testing
uses gas or liquid to ﬁll the bladder to allow assessment of
bladder volume, compliance, and sensation as well as doc-
umenting whether uninhibited bladder activity is present.
Bladder pressures are monitored during ﬁlling and emptying
by use of a transurethral catheter connected to a pressure
transducer, and intra-abdominal pressure is often measured
as well. During the examination, bladder sensations are
determined including sensation of bladder ﬁlling (which
normally occurs between 100–200cc), ﬁrst urge to void
(which normally occurs between 300–400cc), and strong
urge to void (which normally occurs between 400–500cc).
Normal bladder capacity is 300–600cc generally. Sphincter
electromyography using surface or needle electrodes is
performed simultaneously to determine if voiding is coor-
dinated or not (i.e., whether detrusor sphincter dyssynergia
is present).
Bladder leak point pressure is the maximum detrusor
pressure measured during passive ﬁlling before urine leakage
occurs. Sustained high detrusor pressures may occur in
neurogenic bladders having poor compliance, and leak point
pressures over 40cm H2O places the upper urinary tract at
increased risk for damage [17].
Urethral pressure proﬁle (UPP) is a measure of the
outﬂow resistance within the urethra. Several techniques
have been described but most commonly it is measured by
recording pressures along the length of the urethra during
slow withdrawal of a water-ﬁlled urethral catheter connected
to a pressure transducer. UPP is most commonly performed
after cystometry, and thus comparing the peak urethral
pressure to the pressures measured in the detrusor during
cystometrogram can provide clinically beneﬁcial informa-
tion about bladder emptying potential. UPP has several
clinical applications including the diagnosis of stress urinary
incontinence, urethral instability, and urethral diverticula,
but its utility for diagnosing and treating neurogenic bladder
is less clear [18].
5. Neurogenic Bladder Management
Management of neurogenic bladder conditions requires
patient education and may include interventions such as
timed voiding, manual expression, medications, intermittent
catheterization, indwelling urinary catheter, and bladder
and/or urethral surgical procedures.6 Advances in Urology
5.1. Nonpharmacologic Interventions
5.1.1. Bladder Retraining and Fluid Schedule. The goals of
management of neurogenic bladder are to (1) achieve/
maintain continence to avoid the psychological and physical
(e.g., skin maceration and decubiti) consequences of incon-
tinence, (2) prevent development of a high pressure detrusor
that can lead to upper urinary tract damage, (3) minimize
risk of symptomatic urinary tract infections, and (4) prevent
over-distension of the bladder.
Initiation of a ﬂuid schedule is an important initial
intervention in the management of neurogenic bladder
patients requiring intermittent catheterization as part of
their neurogenic bladder management and may also be
of help in patients with uninhibited neurogenic bladder
dysfunction. A ﬂuid schedule allows a predictable degree of
bladder ﬁlling without overdistending the detrusor. Repet-
itive overdistension of the detrusor can lead to permanent
muscle damage, producing a ﬂaccid, large capacity bladder
(i.e., a myogenic bladder). This is especially important if the
neurogenic bladder dysfunction is potentially a temporary
clinical situation (e.g., urinary retention following cauda
equina syndrome from lumbar disc herniation).
The recommended ﬂuid schedule is 400cc with meals;
200cc at 10am, 2pm, and 4pm; and then only sips of ﬂuid
after the evening meal (1800cc/day total). Accounting for
insensible ﬂuid loss with respiration and sweating, this ﬂuid
schedule keeps urine formation limited to about 1600cc
per day. If urinary catheterization is then performed on an
every 6 hours schedule, the catheterized volumes will be
approximately 400cc each. This prevents bladder overdis-
tension, and catheterization should be frequent enough to
optimally keep bladder volumes to 400–500cc. If neurogenic
bladder management consists of an indwelling Foley catheter
or suprapubic catheter, then ﬂuid intake should be generous.
Thepresenceofthecatheterinthebladderresultsinbacterial
colonization there that produces a bioﬁlm on the catheter tip
[19]. Urease producing bacteria in the bladder elevate urine
pH causing calcium and magnesium phosphate crystals to
form in the urine which cause encrustation of the catheter
and potentially obstruction [20]. Obstruction of the catheter
is associated with an elevated risk of urinary tract infections
as is low urinary output [21]. Increasing dietary citrate to
at least 11g per day in fruit juices to keep urine pH > 8
in conjunction with increasing ﬂuid intake to dilute urine
calcium and magnesium concentrations [22]c a np r e v e n t
catheter encrustation, especially if total daily ﬂuids are at
least 3 liters per day [20].
Individualized patient education regarding management
of their neurogenic bladder via specialized nursing is impor-
tant for achieving successful neurogenic bladder manage-
ment. Nurses can monitor patient compliance with ﬂuid
schedule and teach patients how to perform timed voids
as well as manual techniques including self-catheterization,
Crede technique (manual pressure over suprapubic region
to increase vesicular pressure to promote bladder emptying),
tapping(oversuprapubicareatotriggerdetrusorcontraction
in hyperreﬂexic bladders), and/or Valsalva maneuver (which
increases vesicular pressure and may also trigger detrusor
contraction).
The use of incontinence pads or external urinary col-
lection devices such as condom (Texas) catheters as the
sole interventions for long-term management of neurogenic
bladder dysfunction is rarely appropriate. Absorbent incon-
tinence pad use can lead to skin maceration and breakdown
and increase the risk of urinary tract infections about 4 fold
[23]. This may be mitigated by frequent change of pads.
Condom catheters are appropriate for incontinent males
without urinary retention who have signiﬁcant functional
impairments [24]. For example, a male with an uninhibited
bladder and severe hemiparesis following a stroke may be
an appropriate candidate for a condom catheter for man-
agement of his incontinence. Condom catheters are more
comfortable and have a lower incidence of bacteriuria than
indwelling urethral catheters [25]. Though skin breakdown
commonly occurs, other complications such as urethral
diverticuli and penile ischemia are uncommon [26].
Clean intermittent catheterization is the preferred
methodofbladdermanagementforpatientswithneurogenic
bladder dysfunction with partial or complete urinary reten-
tion. Regular bladder emptying reduces intravesical bladder
pressure and improves blood circulation in the bladder
wall, making the bladder mucous membrane more resis-
tant to infectious bacteria [27]. Intermittent catheterization
improves self-care and independence and reduces barriers to
sexual intimacy compared to use of an indwelling catheter.
If the patient with neurogenic bladder dysfunction has some
ability to perform voluntary voiding, then voiding attempts
are attempted every 3 hours while awake including just-
before-intermittent catheterization attempts. If the voiding
attempts enable the patient to empty the bladder suﬃciently
so that residual urine volume in the bladder is under 100cc
consistently, then the catheterization can be discontinued.
Residual urine volumes under 100cc are associated with a
reduced risk of development of bacterial cystitis [14].
The tip of a catheter used for intermittent catheterization
c a nb ee i t h e rs t r a i g h to rc u r v e d( r e f e r r e dt oa sC o u d ´ e-
tipped). A closed intermittent catheterization system is
availablewhichisdesignedtoreducetheriskofbacterialcon-
tamination of the bladder during insertion since the catheter
never comes into direct contact with the inserter’s hands.
Medicare and Medicaid will cover these closed-catheter sys-
tems with introducer tips for persons requiring intermittent
self-catheterization who are immune-compromised, nursing
home residents, experiencing documented vesicoureteral
reﬂux, pregnant spinal cord injured females with neurogenic
bladder, and/or having two or more urinary tract infections
per year with clean intermittent catheterization.
Themostfrequentcomplicationofintermittentcatheter-
ization is urinary tract infection. Studies show that in
patients with spinal cord injuries, the incidence of bacteria
in the bladder is 1–3% per catheterization and that 1–4
episodes of bacteriuria occur per 100 days of intermittent
catheterization.Wyndaele’sreviewoftherisksofintermittent
catheterizationindicatesan11%prevalenceofasymptomatic
urinary tract infections and 53% prevalence of symptomatic
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prophylactic antibiotics for intermittent catheterization is
controversial, but use of low dose sulfamethoxazole or
nitrofurantoin at night may reduce the risk of symptomatic
bacterial cystitis without encouraging drug-resistant bacte-
ria. Prostatitis may occur in up to a third of men performing
intermittent catheterization, but epididymitis and urethritis
are rare. Catheter trauma is common but generally does
not produce lasting damage, though the prevalence of
urethral strictures and false passages increases with duration
of intermittent catheterization use. Rare complications of
intermittent catheterization include formation of bladder
stones, loss of catheter in the bladder, bladder perforation,
bladder necrosis, and bladder cancer.
Indwelling Foley catheter placement for neurogenic
bladder management is an option for uncontrollable incon-
tinence or for urinary retention when intermittent catheter-
ization is not practical. Estimates are that nearly 4 million
Americans a year undergo indwelling urinary catheter
placement, including up to a quarter of patients in acute
care facilities and 5–10% of those in long-term care facilities
for over a year [29, 30]. Duration of catheter use in
home settings may be rather long, with a median of 3-
4 years, and some individuals may use them for more
than 20 years [31]. For example, myelomeningocele patients
may have impaired motor and/or intellectual function that
make-self-clean intermittent catheterization impossible so
indwelling urinary catheters may allow them to maintain
independence.Onestudynoted12%oftheirmyelomeningo-
cele cohort used indwelling catheter for long-term bladder
management [32, 33]. In the setting of long-term indwelling
urinary catheter placement, antimicrobial prophylaxis to
prevent urinary tract infection should be avoided as it will
result in development of drug-resistant bacterial organisms
colonizing the bladder. Instead, as previously discussed,
patients with indwelling Foley catheters should maintain
high (>3 liters/day) oral ﬂuid intake to keep the colonized
bacteria ﬂushed from the bladder and the catheter should
be changed monthly. Other complications of indwelling
catheters include bleeding, urethral or bladder injuries,
bladder sediment/stones, catheter malfunction (including
obstructions), bladder perforation, rectovesical ﬁstula, and
bladder cancer [29, 34–36]. For male patients, many experts
recommend using the smallest diameter urinary catheter
feasible and to tape it to the lower abdominal wall under low
tension to minimize the risk of urethral erosions [37].
Suprapubic cathetershave some advantagesover urethral
catheters including elimination of those urethral erosion
risks. Suprapubic catheters also are usually easier to manage
in terms of hygiene and catheter changes, have less chance
of catheter kinking, are easily reversible, and may cause less
interference with self-image and sexual intimacy than with
use of Foley catheters when used for long-term bladder
management. Signiﬁcant surgical risks exist, however, for
suprapubic catheter insertions. A retrospective study of 219
patientsfoundasurgicalcomplicationrateof10%(mortality
rate 1.8%) with a 30-day complication rate of 19% [38].
These high complication rates likely reﬂect the underlying
medical comorbidities in this patient population. Beyond
expected elevated risks of urinary tract infections (21%)
in long-term followup, a quarter of the cohort experi-
enced catheter obstruction and less frequent complications
included exit site infection/granulation/bleeding, bladder
spasms, and catheter technical diﬃculties. Despite this, 71%
ofthiscohorthadpriorunsatisfactoryexperienceswithFoley
catheters prior to opting for suprapubic catheter insertion,
and nearly 90% preferred their suprapubic catheter over
a urethral catheter. Bladder stones occur in up to 65% of
individuals with suprapubic catheters compared to 30% of
those performing intermittent catheterization [39]. There
are rare reports of bladder cancer, though with less than
half the risk associated with use of urethral catheters [36].
Suprapubic catheters should also be changed routinely, and
some experts [40] recommend changing the catheter at the
average time it takes for the catheter to obstruct for each
patient (one to several weeks).
5.2. Pharmacologic Interventions. There are many diﬀerent
classes of drugs that are used to treat neurogenic bladder
dysfunction as part of acomprehensive bladder management
program.
5.2.1. Tricyclic Antidepressant Drugs. Though initially devel-
oped for the treatment of depression, their signiﬁcant
adverse side eﬀect proﬁles have made them second-line
agents for that indication. Serious side eﬀects of tricyclic
antidepressants exist including sedation, orthostasis, and
cardiac conduction blocks; these drugs should particularly
be used with caution in older individuals having neurogenic
bladder dysfunction. Tricyclics should not be used in setting
of pregnancy. The anticholinergic side-eﬀects of this class
of drugs have been used to reduce bladder detrusor tone
in neurogenic bladder dysfunction as an oﬀ-label (non-FDA
approved indication) use.
Imipramine not only reduces bladder tone through its
strong anticholinergic eﬀects and antispasmodic properties
but it also increases bladder internal sphincter tone through
α-adrenergic agonist eﬀect to further facilitate urine storage.
Additionally, imipramine has a local anesthetic eﬀect on
bladder mucosa, which may further reduce bladder contrac-
tility through spinal reﬂex mechanisms. Imipramine thus
may be useful to reduce urinary urgency and frequency in
uninhibited bladder dysfunction. Amitriptyline has (rela-
tively) less anticholinergic eﬀects than imipramine, yet it is
similarly eﬀective in reducing detrusor tone. Amitriptyline
has strong sedation properties and may also be helpful in the
treatment of neuropathic pain conditions and insomnia.
5.2.2. Anticholinergic (Antimuscarinic) Medications. This
class of medication reduces reﬂex (involuntary) detrusor
activity by blocking cholinergic transmission at muscarinic
receptors and is the ﬁrst-line option for treating neurogenic
detrusor overactivity (NDO). Though available anticholin-
ergic agents have similar eﬃcacy, these drugs diﬀer in terms
of side eﬀects and tolerability based on their muscarinic
receptor selectivity and rate of drug distribution. Anti-
cholinergic drugs that bind M1, M2, and M3 muscarinic
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agents that are more selective for M2 and/or M3 receptors.
Sustained release drug preparations also improve antimus-
carinic drug tolerability by attenuating peak drug serum
concentrations.
Nonselective anticholinergic drugs that bind M1 recep-
tors may produce memory and cognition impairments.
Agents binding M2 receptors can produce QT interval
prolongation causing tachycardia and arrhythmias. Anti-
cholinergic drugs that bind M3 receptors may produce visual
blurring, xerostomia, and constipation.
Nonselective anticholinergic agents include oxybutynin,
tolterodine, and trospium chloride. Oxybutynin, which
was the ﬁrst drug approved for treating bladder detrusor
overactivity, is available in immediate and sustained release
oral preparations as well as transdermal and topical gel
formulations. Tolterodine also comes in immediate and
sustained release oral preparations, and may produce less
xerostomia and cognitive side eﬀects than oxybutynin.
Trospiumalsoisavailableinimmediateandsustainedrelease
oral preparations. Since trospium does not cross the blood
brain barrier, cognitive side eﬀects are diminished and it may
have fewer drug-drug interactions compared to the other
Nonselective anticholinergic agents.
Anticholinergic drugs that are more selective for M2
and M3 receptors, have fewer cognitive side eﬀects than
Nonselective agents. Solifenacin and darifenacin are more
selective for M3 receptors so these agents may be safer to
use in individuals having heart disease but may tend to pro-
duce more constipation than Nonselective anticholinergic
medications (consider avoiding in patients with preexisting
constipation issues). Darifenacin dosing does not have to be
adjusted for renal impairment. Fesoterodine is a competitive
muscarinic antagonist that does not appear to cause QT
prolongation or cognitive impairments. Imidafenacin is a
selective anticholinergic drug currently undergoing clinical
trials in the United States but available in Japan.
Trospium or fesoterodine may be better therapeutic
options for patients with hepatic impairment, since they
are not processed by the CYP3a4 system, while darifenacin
should be avoided in patients with severe hepatic impair-
ment. If bladder overactivity symptoms continue despite a
maximum dose of an anticholinergic agent for a month
without signiﬁcant side eﬀects, then addition of a tricyclic
agent may provide a synergistic eﬀect in reducing detrusor
tone.
Manack et al. [3] found 63% of persons diagnosed
with neurogenic bladder were taking one-anticholinergic
medication and another 9% more than one. Over a one
year period, 38% of neurogenic bladder discontinued their
anticholinergic medication(s) and did not restart while over
80% of patients had interruption of their treatment with
these medications. During the one year study period, 33.3%
(15,415) of the neurogenic bladder cohort required hospi-
talization, 23.4% (10,819) had emergency room admissions,
and 14.4% (6,646) resided in a nursing home. Over 21%
of hospitalized patients in their cohort were diagnosed
with lower urinary tract infections, and approximately 8%
were hospitalized with sepsis/septicemia. Of the one-third
of neurogenic patients that were hospitalized, 5.6% were
diagnosed with urinary retention and 5.4% were diagnosed
with obstructive uropathies.
Propiverine is a drug with antimuscarinic and calcium
antagonist properties that is available in Europe and Japan
and is reported to have few adverse reactions (mainly dry
mouth and blurred vision). Though mainly used for treating
overactive bladder, it has been used in spinal cord injured
patients where it increased bladder capacity over 100cc and
improved bladder compliance [41]. Residual urine volume,
however, increased from 50cc to 87cc in the propiverine
group.
5.2.3. Cholinergic Agonists. Urecholine is a synthetic mus-
carinic agonist with no signiﬁcant nicotinic eﬀects. It can
be used to promote detrusor contraction in mixed type A
or lower motor neuron lesions. Urecholine is administered
about one hour before meals and at bedtime as part of the
bladder training program in which voiding attempts and
often manual techniques (Valsalva or Crede) are performed
before the scheduled intermittent catheterization attempts
every 6 hours. As a cholinergic agonist, urecholine can
p r o d u c es i d ee ﬀects including hypotension, bradycardia,
bronchoconstriction, nausea/vomiting, abdominal cramp-
ing, and diarrhea. It should be used with caution in
personswithasthma,chronicobstructivepulmonarydisease,
hyperthyroidism, peptic ulcer disease, intestinal obstruction,
urinary tract obstruction, coronary artery disease (especially
if conduction blocks), or Parkinsonism.
5.2.4. Alpha-2 Adrenergic Agonists. This class of medications
can be used in neurogenic bladder dysfunction when the
internal urinary sphincter is spastic, which occurs with
detrusor sphincter dyssynergia in upper motor neuron blad-
der dysfunction. Alpha-2 adrenergic agonists cause presy-
naptic reduction of norepinephrine release at central and
peripheral adrenergic terminals. Since the internal urinary
sphincter has alpha-adrenergic innervation (see Figure 1),
these agents can enhance bladder emptying by reducing
bladder neck tone.
Alpha-2 adrenergic agonists are seldom, the sole med-
ication used for treating neurogenic bladder dysfunction,
since detrusor hyperreﬂexia must be addressed to prevent
upper urinary tract damage. Even in the setting of complete
or nearly complete bladder emptying, persistent elevation
of detrusor pressures can produce progressive renal damage
from hydronephrosis.
Clonidine and tizanidine are alpha-2 agonists that have
been used for reducing bladder outﬂow resistance. These
agents have also may be used clinically to reduce pain and
skeletal muscle tone, which may potentially produce beneﬁ-
cial side-eﬀects in treating neurogenic bladder dysfunction
in spinal cord injured patients. Tizanidine is administered
orally. Clonidine is available in oral and transdermal forms,
and intrathecal administration of this drug has also been
studied as a potential treatment modality for refractory
neurogenic bladder dysfunction.
Common side eﬀects of these drugs include fatigue,
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Cardiac dysrhythmias and depression are uncommon but
s e r i o u ss i d ee ﬀects.
5.2.5. Alpha-1 Adrenergic Antagonists. Alpha-1 adrenergic
antagonists such as dibenzyline, terazosin, tamsulosin, alfu-
zosin, and doxazosin produce peripheral postsynaptic block-
ade of alpha-adrenergic receptors in the bladder neck and
proximal urethra to reduce urinary outﬂow resistance. Their
vasodilating eﬀe c to na r t e r i a ls m o o t hm u s c l ep r o d u c e sa
reduction in blood pressure. Alpha-1 adrenergic antagonist
drug side eﬀect proﬁles are similar to those of the alpha-2
adrenergic agonists as outlined above.
5.2.6. Benzodiazepines. Benzodiazepines such as diazepam
are believed to exert their clinical eﬀects by binding at
a speciﬁc site on the GABA-A receptor to potentiate the
eﬀects of the inhibitory neurotransmitter GABA (gamma
amino butyric acid). Benzodiazepines bind at spinal and
supraspinal sites to reduce skeletal muscle tone, including
the external urinary sphincter. Thus, diazepam has been
used clinically to treat external sphincter spasticity from
upper motor neuron or mixed type A neurogenic bladder
dysfunction. The resulting reduction in bladder outﬂow
resistance may allow more complete bladder emptying.
Side eﬀects of benzodiazepines include sedation, delir-
ium, respiratory depression, muscle weakness, constipation,
and blurred vision. Benzodiazepenes can produce physical
and psychological dependence as well.
5.2.7. GABA-B Agonists. Baclofen is the most commonly
used drug of this class clinically, and it is believed to exert its
clinical eﬀects through modulation of the GABA-B receptors
at spinal and supraspinal levels to reduce skeletal muscle
tone. Thus, like the benzodiazepines, baclofen can be used
to treat external urinary sphincter spasticity in neurogenic
bladderconditions.Baclofenhasaclinicaladvantageoverthe
benzodiazepines in this regard as it does not appear to cause
any tendency towards psychological dependence.
Baclofen can also be administered intrathecally for
refractory spasticity conditions, especially where oral anti-
spasticity agents produce excessive sedation or other intol-
erable side eﬀects.
5.2.8. Botulinum Toxin. Botulinum toxin blocks neuromus-
cular junction presynaptic vesicle fusion, which prevents
acetylcholine release and thus blocks signal transmission
across the neuromuscular junction [5]. It also acts on
sensory aﬀerent neurons and prevents the excitatory eﬀects
of nerve growth factor (NGF) on bladder function, which
may contribute to its beneﬁcial clinical eﬀects in treating
neurogenic bladder. Injection of botulinum toxin A into
the bladder detrusor or external urinary sphincter produces
a dose-dependent weakening of those muscles, which have
a high concentration of cholinergic nerve endings (see
Figure 1). Botulinum toxin A injections can produce long-
lasting improvements in neurogenic detrusor overactivity,
incontinence, and quality of life in spinal cord injury
individuals. Since insurance coverage for botulinum toxin
for these urologic indications is often limited, this mode of
intervention should be reserved for individuals where oral
and transdermal trials of medications have failed.
Dykstraetal.[42]ﬁrstreportedusingbotulinumtoxinto
successfully treat urinary symptoms by injection of external
urinary sphincter of spinal cord injured patients having
detrusor sphincter dyssynergia. Injection of botulinum
toxin A into bladder detrusor muscle to treat neurogenic
incontinence was described a decade later [43]. Botulinum
toxin A injection in the detrusor and suburothelial regions
of the bladder body can produce beneﬁcial eﬀects for
up to nine months, though up to 70% of neurogenic
detrusor overactivity patients may require catheterization
after botulinum toxin injections due to urinary retention.
Sideeﬀectsofbotulinumtoxininjectionsarelow,witha<1%
risk of developing antibodies to the toxin [44]a n da b o u ta
1% incidence of temporary distant muscle weakness [45].
Approximately 10% of patients do not obtain the desired
clinical beneﬁt from the botulinum toxin injections.
A large, retrospective trial of 200 neurogenic blad-
der patients receiving detrusor botulinum toxin injections
demonstrated a >50% increase of mean bladder volume to
ﬁrst reﬂex detrusor contraction and maximum cystometric
capacity, with a proportional decrease in maximum detrusor
pressure. These beneﬁts lasted more than 6 months and
could be more cost eﬀective than bladder augmentation
surgeryovera5-yearperiodifa40%earlyandlatecomplica-
tion rate of that surgery is assumed and the botulinum toxin
eﬀect lasted at least 5 months [46].
For instances in which neurogenic bladder dysfunction is
refractory to these medications, several novel pharmacologic
options are in development including intravenous, intraves-
icular, and intrathecal agents.
5.2.9. Opioids. Agonists of the classical μ, δ,a n dκ opioid
receptors such as morphine interfere with voiding, while
antagonists of those receptors such as naloxone stimulate
voiding. Intrathecal administration of the δ-receptor ago-
nists inhibits detrusor contractions, while κ-receptor ago-
nists administered intravenously reduce detrusor sphincter
dyssynergiainexperimentalspinalcordinjuryanimalstudies
[47].
Nociceptin (orphanin FQ) is an endogenous neuropep-
tide that binds to the nociception receptor (NOP). It inhibits
the micturition reﬂex in neurogenic incontinence conditions
but not in healthy persons, and intravesicular administration
ofthiscompoundhasbeendemonstratedtoimprovebladder
function in spinal cord injured individuals [48].
5.2.10. Vanilloids. Intravesical administration of vanilloid
solutions, such as capsaicin or resiniferatoxin (RTX),
reduces detrusor overactivity by selectively desensitizing the
unmyelinated C-ﬁber sensory nerves that transmit urothelial
pain and temperature sensation. At high concentrations,
these drugs suppress C-ﬁber responses to stimulation
for prolonged periods. Increased expression of transient
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1 (TRPV1) vanilloid receptors in urothelial cells and C-
ﬁbers occurs following spinal cord injury, and experimental
evidence suggests that activation of these receptors may
be involved in the resulting detrusor overactivity. Intrav-
esicular administration of capsaicin or RTX then could
serve to reduce detrusor hyperreﬂexia due to spinal cord
lesions.
Clinical studies have conﬁrmed that intravesicular vanil-
loid solutions do improve neurogenic detrusor overactivity
associated with spinal cord injury or multiple sclerosis,
including a double-blind, randomized controlled study
demonstrating that intravesicular capsaicin signiﬁcantly
inhibited spinal cord-associated detrusor overactivity [49].
Intravesicular capsaicin acutely may, however, cause tran-
sient exacerbation of bladder symptoms which does not
occur with intravesicular RTX. One small study of intrav-
esicular RTX in neurogenic detrusor overactivity found
resolution or improvement of urinary incontinence in 75%
of patients with those urologic improvements sustained for
at least a year in 58% [50]. RTX can also be administered
intrathecally to treat detrusor overactivity.
Clinical use of vanilloids has been hampered by their
pungency and lack of stability of vanilloid solutions. Oral
TRPV1 antagonists (e.g., GRC 6211) are being developed to
avoid these issues, and in animal spinal cord injury studies
these drugs reduce high intravesicular pressures and reﬂex
bladder contractions [51].
5.2.11. Nerve Growth Factor. Urinary nerve growth factor
( N G F )h a sb e e nd e m o n s t r a t e dt ob ee l e v a t e di nn e u r o g e n i c
detrusor overactivity (Jacobs). This neurotrophic factor
induces changes in the excitability of bladder aﬀerents, and
sequestration of NGF improves bladder reﬂex activity in
animal models [52]. Compounds are being developed to
sequester NGF to treat neurogenic detrusor overactivity.
5.2.12. Nitrous Oxide Agonists. Experimental evidence sug-
gests nitric oxide synthase-staining neurons are present in
high density in human urethral sphincters, with activation
of this mechanism producing reduction in urethral pressure
[53]. Theoretically, since the urethral sphincter has excellent
blood supply, oral or sublingual nitrates (presently used to
treat angina) could be used to reduce external sphincter
pressure in patients with detrusor sphincter dyssynergia.
Carbon monoxide also relaxes urethral smooth muscles, and
carbon monoxide-synthesizing enzymes (hemeoxygenase-
2) coexist with nitric oxide synthase enzymes in neurons
supplying the external sphincter [54], so this physiologic
mechanism oﬀers another avenue for drug development in
the future.
6. Surgical Interventions for
Neurogenic Bladder
When nonpharmacologic and pharmacologic treatments fail
to control neurogenic detrusor overactivity, then surgical
options including neuromodulation are appropriate treat-
ment options.
6.1. Procedures to Enhance Detrusor Storage
6.1.1. Neuromodulation for Neurogenic Detrusor Overactivity.
Unilateral or bilateral sacral nerve root stimulation tech-
nology used for overactive bladder treatment has also been
applied to neurogenic detrusor overactivity. A recent system-
atic review and meta-analysis [55] of this topic reported a
pooled success rate of 92% for sacral neuromodulation for
neurogenic bladder and 24% complication rate, though a
lack of randomized controlled trials was noted and mean
followup of studies examined was only 26 months. The most
frequent adverse events of sacral nerve root stimulation were
lead migration and pain at the site of the implant. Removal
of the lead or stimulator was the most frequent surgical
intervention resulting from adverse events.
Long-term studies suggest the eﬃcacy of sacral neu-
romodulation may disappear after 1–4 years. A long-term
study of 12 adult neurogenic bladder patients undergoing
sacral neuromodulation implantation by Hohenfellner et
al. [56] found that one stimulator had to be removed in
the immediate postoperative period, and stimulation was
ineﬀective in another three patients. The other 8 patients
had at least 50% improvement of lower urinary tract
dysfunction for an average of 4.5 years, but then all but
one sacral neuromodulation implant became ineﬀective
after this time frame. A prospective randomized controlled
study of 42 children (mostly with spina biﬁda) undergoing
sacral neuromodulation for neurogenic bladder dysfunction
management found better functional bladder capacity on
urodynamicsinthecontrolgroupbuthigherleakpoint pres-
sure in the implant cohort. Improved bladder compliance
and functional bladder capacity were noted in the implant
group for the ﬁrst 9 months of followup, but not after 12
months [57].
Combining dorsal rhizotomy to reduce detrusor pressure
and sacral root stimulation to drive micturition has been
d e s c r i b e dt ot r e a tu p p e rm o t o rn e u r o nb l a d d e rd y s f u n c t i o n
in female paraplegics, though this combination of proce-
dures can be used in male paraplegics and quadriplegics as
well as with the caveat that reﬂex erections (if present) may
be lost due to the rhizotomy [58].
Chronicpudendalnervestimulationhasbeenstudiedfor
urge incontinence due to neurogenic detrusor overactivity
[54]. Though followup in the study of Spinelli et al. was
only 6 months, the twelve individuals undergoing chronic
pudendalnervestimulationmorethandoubledtheirbladder
capacity to over 330cc with 56% reduction of maximum
detrusor pressure to 36.8cm H2O.
6.1.2. Enterocystoplasty. Enterocystoplasty, in which blad-
der capacity is increased (and its pressure simultaneously
lowered) by anastomosing a part of the ilium or ileocecal
segment to the detrusor, is generally accepted as the most
eﬀective surgical method to achieve an adequate reservoir
of urine. The success rate of enterocystoplasty is reported
to be as high as 90% [59]. Bladder augmentation has been
performed in 25–30% of individuals with meningomyelocele
[32]. This procedure is major surgery, however, with an
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the longest mean followup [60]. Surgical complications of
enterocystoplasty include infections, anastomotic leakage,
strictures, adhesions, intestinal obstruction, urinary ﬁstulas,
enteric ﬁstulas, and bladder rupture [59]. Robotic ente-
rocystoplasty has been described [61] which may reduce
some of the surgical complications of this procedure. Other
potential complications of enterocystoplasty include mucus
formation,bladdercalculi(2–18%),electrolytedisturbances,
and an elevated risk of bladder adenocarcinoma (approxi-
mately 1%).
After enterocystoplasty, the neurogenic bladder patient
may be able to void normally, but it is possible that an exter-
nal urine collection device may be required. The number
of patients needing to perform intermittent catheterization
following enterocystoplasty has been reported to range from
15%–75% [59].
Bladder autoaugmentation by creating a large detrusor
diverticulum via myomyotomy or myomectomy has also
been performed to increase bladder capacity and reduce
intravesicular pressure. Operative results often were not
optimal in the past due to a bladder diverticulum either
failing to form or being of inadequate capacity. Postoper-
ative ischemia and ﬁbrosis of the diverticulum as well as
recession of the mucosa have been postulated as potential
mechanisms leading to inadequate diverticulum formation.
More recently, the use of an inﬂatable silicon balloon placed
in the bladder after autoaugmentation has been described
[62] which has been reported to improve the success rate of
this procedure to 80% with a 190–380% increase of bladder
capacity and normal bladder compliance [63, 64].
Experimentally, tissue engineering techniques for blad-
der augmentation are being studied including unseeded or
seeded biodegradable biomatrices. Though animal studies
demonstrate that urothelial regeneration can occur with a
varietyofgraftmaterials,muscularlayerregenerationdidnot
occur in synthetic or acellular grafts resulting in ﬁbrosis and
contractionofthegraftin60–70%ofcases[65–67].Implants
made from collagen or PLGA-based scaﬀolds seeded with
autologous progenitor cells have had preliminary positive
results in small clinical studies [68].
6.2. Procedures to Control Detrusor Emptying
6.2.1.UrinaryDiversion. Forpatientswhohaveaneurogenic
bladder with incomplete emptying (lower motor neuron
bladder, mixed type A neurogenic bladder, or following
bladder augmentation procedures) and who have disabilities
that make self-catheterization through the urethra imprac-
tical, a continent abdominal stoma can be created for clean
intermittent catheterization surgically with a >90% success
rate. It still requires a major abdominal surgery, however.
Appendicovesicostomy anastomosis can be performed
on the anterior detrusor wall without the need for bladder
augmentation, or it can be performed on the posterior
bladder wall in conjunction with augmentation. The stoma
can be brought to the umbilical area or to the right lower
quadrant.Byhaving atleast4cmofdetrusorbacking, stomal
continence can be maintained. Pedicled skin ﬂaps have also
been utilized to form catheterizable channels [69, 70].
6.2.2. Bladder Sphincter Procedures to Enhance Emptying
Sphincterotomy. Sphincterotomy, ﬁrst described by Ross et
al. in 1956 [71], has largely been supplanted by use of
botulinum toxin injections, medications, or urethral stents.
By reducing the urinary outlet obstruction, reﬂex voiding
occurs with less detrusor pressure and improved bladder
emptying. Fewer urinary tract infections and reduced risk of
autonomic dysreﬂexia are additional beneﬁts. Most patients
undergoing sphincterotomy have resulting incontinence due
to urinary leakage, so this procedure is generally not an
appropriate choice for women or if use of a condom catheter
is not plausible due to body habitus in male patients.
Indications for sphincterotomy include detrusor sphincter
dyssynergia with hydronephrosis, vesicoureteral reﬂux, and
autonomic dysreﬂexia or recurrent urinary tract infections
due to poor bladder emptying [58]. This procedure is likely
most appropriately reserved for quadriplegic males who are
unable to perform self-intermittent catheterization. Up to
50% of patients with detrusor areﬂexia can have successful
results with sphincterotomy.
Hemorrhage is a signiﬁcant complication of sphinctero-
tomy, but postoperative bleeding may be reduced by using
laser rather than a knife to create the sphincter sectioning
[58]. Erectile dysfunction may occur in 3–7% of males
undergoing sphincterotomy, and this procedure results in
bladder neck or urethral strictures in 3–13% patients that
will require reoperation [58]. Three-quarters or more of
patients undergoing this procedure will have resolution of
vesicoureteral reﬂux and recurrent urinary tract infections,
and over 90% will experience resolution of autonomic
dysreﬂexia. Despite these beneﬁts of sphincterotomy, there
is still an approximate 30% chance that these persons will
undergo upper urinary tract deterioration over time. A leak
point pressure (LPP) of over 40cm H2Oo nu r o d y n a m i c
study after sphincterotomy is associated with a signiﬁcantly
higher incidence of upper tract damage and persistent
detrusor sphincter dyssynergia [58]. Persistent obstruction
due to bladder neck obstruction can be managed by a
trial of alpha adrenergic blocking drugs, bladder neck
incision/resection, or use of an indwelling urinary catheter
(urethral or suprapubic).
Urethral Stents and Balloon Dilatation. Urethral stents can
serve as a therapeutic alternative to sphincterotomy both
as a primary procedure or to treat a failed sphincterotomy
procedure [72]. By strict avoidance of putting the stent
through the bladder neck, the incidence of stent encrustation
and development of dysreﬂexia can be minimized. Though
stent migration may occur, the stents usually can be reposi-
tioned or removed with low incidence of signiﬁcant urethral
trauma. Recurrent urinary tract infections may be a relative
contraindication to this procedure [73] due to risk of stent
infection. This procedure may have a theoretical advantage
over sphincterotomy in that weight gain, wheelchair seating
position,andpelvicﬂoorspasticitymaywellcausefunctional
urethral obstruction that will not be detected by urodynamic
studies.12 Advances in Urology
Balloon dilatation of the external sphincter has also
been studied and produces outcomes at 12 months that
are comparable to sphincterotomy [74] Long-term followup,
however, suggests that the results of balloon dilatation of the
external urethral sphincter may not produce durable results
[75].
6.2.3. Bladder Sphincter Procedures to Restrict Emptying
Artiﬁcial Urinary Sphincter. Artiﬁcial urinary sphincter
devices are presently the “gold standard” method to treat
urinary incontinence due to internal and/or external urinary
sphincterincontinence,witha75–95%socialcontinencerate
(<1 incontinence pad use per day) reported at three year
followup in male, female, and pediatric populations [76].
Implantable artiﬁcial urinary sphincters have been in
clinical use since 1972, butearly devices hadhigh mechanical
failure and urethral erosion rates. Over the next decade,
design improvements produced more reliable devices that
produced acceptable complication rates; and nearly 100,000
artiﬁcial urinary sphincters have been implanted over the
last three decades. This intervention may be considered in
neurogenic bladder patients with adequate bladder capacity
and compliance, who have internal and/or external urinary
sphincter incompetence resulting in urinary incontinence
unresponsive to bladder retraining and pharmacologic
approaches. Further, these patients must have suﬃcient
learning capacity and hand strength/dexterity to operate the
pump and its valve mechanisms.
If bladder capacity and/or compliance are low, bladder
augmentation procedures may be combined with artiﬁcial
sphincter replacement for treatment of the neurogenic
bladder dysfunction. Urethral diverticula or strictures are
contraindications to the artiﬁcial urinary sphincter. Relative
contraindications include recurrent bladder stones, ≥ grade
2 vesicoureteral reﬂux (which may worsen after the artiﬁcial
urinary sphincter placement), or urethral or bladder tumors
that will require future repeated urethral instrumentation
(repeated instrumentation can damage the artiﬁcial sphinc-
ter device’s urethral cuﬀ).
Up to 35% of patients undergoing artiﬁcial sphincter
implantation may require reoperation, with about half of
these reoperations due to device mechanical failures. Loss of
ﬂuidfromtheartiﬁcialsphincterhydraulicsystemproducing
loss of cuﬀ ﬁlling and hence recurrent incontinence is the
most common reason for device failure but air in the system,
debris, blood, and/or crystals may obstruct urinary ﬂow.
The artiﬁcial urinary sphincter devices generally last for
approximately a decade. The most common nonmechanical
reason for reoperation is urethral tissue atrophy leading to
inadequate urethral compression from the cuﬀ resulting in
recurrent urinary leakage (3–9%). Deﬂation of the artiﬁcial
urinary sphincter cuﬀ overnight may reduce the risk of
urethral tissue atrophy. Replacement of the cuﬀ with a
smaller cuﬀ,t a n d e mc u ﬀ placement [77], and higher balloon
pressure (to increase urethral closing pressure) are treatment
options for artiﬁcial urinary sphincter failure; due to tissue
atrophy. Device infections (2-3%) may occur, and cuﬀ
erosions may occur in 1–3% with early erosions (<4 months
postoperativly) thought likely to relate to unrecognized
bladderneckorurethratrauma,andlateerosionsmaybedue
to intermittent catheterization, cuﬀ infection, or pressure
necrosis from excessive balloon pressure or undersized cuﬀ
[78, 79]. Retrograde instrumentation such as cystoscopy
or catheterization, and prior pelvic radiation are also risk
factors for cuﬀ erosions. If cuﬀ erosion into the urethra
occurs, a catheter is placed for 3-4 weeks to allow the urethra
to heal. Typically, surgery to place a new cuﬀ would occur
3–6 months later. Rarely, cuﬀ migration may occur.
Sling Procedures. Artiﬁcial urinary sphincter and/or bladder
neck reconstruction is commonly used clinically to treat
neurogenicdetrusoroveractivitywithlowValsalvaleakpoint
pressure(asisoftenseenwithspinalcordinjurywithdamage
to thoracolumbar sympathetic outﬂow). Rates of artiﬁcial
urinary sphincter device infection and erosion, however, are
higher in persons with neurogenic bladder due to this type
of cord injury [80]. Thus, a bulbourethral sling procedure
in conjunction with a bladder augmentation procedure may
be a reasonable alternative in this clinical setting. If detrusor
contractility is impaired such as in lower motor neuron
or mixed type B neurogenic bladder, a bulbourethral sling
proceduremayleadtourinaryretention.Anartiﬁcialurinary
sphincter may be better option if catheter free voiding is the
goal of surgical treatment.
A 66–83% success rate for the bulbourethral sling
procedure is reported with rare complications after one-
year followup [81, 82], but the long-term eﬃcacy of this
procedure is unknown.
7.FutureDevelopments
7.1. Lumbar to Sacral Nerve Rerouting. Restoring bladder
function in spina biﬁda by creation of a skin-central
nervous system bladder reﬂex arc via lumbar (L5 motor)
to sacral (S3) nerve rerouting has a reported success rate
of 87% in 110 children in China [83]. Recently the one-
year results of the ﬁrst North American trial were reported,
with 7/9 (87%) of spina biﬁda subjects having measurable
increaseinbladderpressurewithL5dermatomalstimulation
(>10cm H2O), most demonstrating a modest increase in
bladder compliance, and all stopping antimuscarinic drugs.
Two subjects were able to stop catheterization, but none
achieved complete urinary continence [84]. One patient had
a persistent foot drop after this surgery. These outcomes
diﬀer substantially from the Chinese experience, and the
improvements in continence and bladder compliance may
relate to sectioning of the S3 nerve root in the procedure.
This should still be considered an experimental procedure
until further prospective data on its eﬃcacy and eﬀects on
quality of life can be determined.
7.2. Spinal Cord Regeneration. Transplantation of ﬁbroblasts
genetically modiﬁed to express brain-derived neurotrophic
factor (BDNF) and neurotrophin 3 (NT-3) or transplanta-
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lesions experimentally induced in rats has been reported
to result in decreased detrusor pressures and less frequent
detrusor hyperreﬂexia episodes [85, 86]. Implantation of
neurotrophin-secreting Schwann cells into rat spinal cord
lesions one hour after induced thoracic cord injury led
to improved bladder morphology and bladder capacity
[87]. Park et al. [88], however, noted that implantation of
mesenchymal stem cells 9 days after experimental thoracic
cord injury in rats did not signiﬁcantly improve bladder or
hindlimb function and noted no increase in BDNF or NT-3
levels in the bladder or spinal cord after 28 and 56 days.
Olfactory ensheathing cells (OECs), which are glial cells
derived from the olfactory placode, have axonal growth
promotingpropertiesintheirinteractionwithastrocytesand
thus have been studied to see if they can promote spinal
cord injury repair. In a pilot study of 30 human subjects
with chronic paraplegia or tetraplegia, Lima et al. [89]
transplantedolfactorymucosalcellautograftsintotheareaof
priorcorddamagewithatleastone-year(andaverageofover
2 year) followup. American Spinal Cord Injury Association
scores improved in 11 subjects but declined in one, and
urodynamic responses were reported improved in 5 subjects.
In spinal cord injury, reactive astrocytes form glial scar at
the site of injury and secrete growth inhibiting chondroitin
sulfate proteoglycans. Epidermal growth factor (EGF) may
stimulate astrocytes to become reactive astrocytes in these
areas of injury, so pharmacologic blockade of EGF receptors
on astrocytes in the site of injury may mitigate damage
there and enhance neurologic recovery (including bladder
function). Erschbamer et al. [90] chronically blockaded EGF
receptors in an acute spinal cord injury in rats using an
osmotic pump subdural infusion of PD168393, an EGF
receptor inhibitor, for 21 days over the site of cord injury.
Locomotor function was found to be improved in the treated
rats, and bladder function was reported as improved as
measured by residual urine volume (though the absolute
diﬀerence was only about 2cc residual urine volume per
day). Chondroitinase ABC intrathecally has also been tested
alone or in combination with cellular transplantation of
OECs and Schwann cells in rats and has been reported
to improve recovery of bladder function in experimentally
spinal cord injured rats at short-term followup [91].
8. Conclusions
Neurogenic bladder dysfunction can be successfully treated
to achieve goals of urinary continence, prevention of
renal damage from chronically high detrusor pressures,
and minimizing risk of urinary tract infections or bladder
overdistension. A comprehensive multidisciplinary bladder
retraining program can best achieve these goals utilizing
patient education, instruction in catheter use/care, med-
ications, and/or bladder or urethral surgical procedures.
Experimental works in lumbar-to-sacral nerve rerouting and
in regenerative medicine including use of stem cells to
mitigateorreversespinalcorddamageproducingneurogenic
bladder dysfunction are still in their infancy, and more
researchwillbeneededtoseeifthepromisingresultsofsome
small pilot studies are conﬁrmed in larger, controlled studies
with long-term followup.
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